Skip to main content
SpringerLink
Log in
Book cover

Manual Gynäkologische Onkologie pp 5–33Cite as

Maligne Erkrankungen der Brustdrüse

  • Chapter

  • 525 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   29.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Albain KS, Allred DC, Clark GM (1994) Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr 16: 35–42

    PubMed  Google Scholar 

  • American College of Radiology (ACR) (1998) Breast imaging-reporting and data system (BI-RADS), 3rd edn. American College of Radiology

    Google Scholar 

  • Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83: 1301–1308

    Google Scholar 

  • Anonymus (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58.209 women with breast cancer and 101.986 women without the disease. Lancet 358: 1389–1399

    Article  PubMed  Google Scholar 

  • Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate and fluouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332: 901–906

    Article  PubMed  Google Scholar 

  • Bonadonna G, Valagussa P (1996) Primary chemotherapy in operable breast cancer. Semin Oncol 23: 464–474

    PubMed  Google Scholar 

  • Boolbol SK, Borgen PI (2001) Sentinel lymph node biopsy: an American perspective. The Breast 10: 287–290

    Article  PubMed  Google Scholar 

  • Clark GM (1996) Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the breast. Lippincott-Raven, Philadelphia, pp 461–485

    Google Scholar 

  • De Laurentiis M, Arpino G, Massarelli E (2000). Proc Am Soc Clin Oncol 19: 300

    Google Scholar 

  • Diagnostik und Therapie des Mammakarzinoms der Frau, Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der beteiligten medizinisch-wissenschaftlichen Fachgesellschaften, Fassung Februar 2003

    Google Scholar 

  • Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403–410

    PubMed  Google Scholar 

  • Empfehlung zur Gewebeaufarbeitung, Anlage zu A6: Pathohistologische Untersuchung zu: Diagnostik und Therapie des Mammakarzinoms der Frau, Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der beteiligten medizinisch-wissenschaftlichen Fachgesellschaften, Fassung Februar 2003

    Google Scholar 

  • Fisher B, Brown A, Mamounas E et al. (1997) Effect of preoperative chemotherapy on loco-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483–2493

    PubMed  Google Scholar 

  • Fisher B (2002) Der Einfluß aktueller Ergebnisse klinischer NSABP-Studien auf Paradigmen zur Behandlung und Prävention des primären invasiven Mammakarzinoms. In: Untch M, Sittek H, Bauerfeind I, Konecny G, Reiser M, Hepp H (Hrsg) Diagnostik unf Therapie des Mammakarzinoms — State of the art 2002. Zuckschwerdt, München Wien New York, S 397–443

    Google Scholar 

  • Fisher ER, Anderson S, Redmond C, Fisher B (1993) Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer 71: 2507–2514

    PubMed  Google Scholar 

  • Gehm BG, McAndrews JM, Jameson JL et al (2000) EGF activates highly selective estrogen-responsive reporter plasmids by an ER-independent pathway. Mol Cell Endocrinol 159: 53–62

    Article  PubMed  Google Scholar 

  • Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ (2001) Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19(18): 3817–3827

    PubMed  Google Scholar 

  • Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21: 3357–3365

    Article  PubMed  Google Scholar 

  • Goss PE, Ingle JN, Martino S et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793–1802

    Article  PubMed  Google Scholar 

  • Hayes DF et al. (1996) A tumour marker utility grading system (TMUGS): a framework to evaluate clinical utility to tumour markers. J Natl Cancer Inst 88: 1456–1466

    PubMed  Google Scholar 

  • Harris JR, Lippman ME, Morrow M, Osborne CK (eds) (2000) Diseases of the breast. Lippincott Williams and Wilkins, Philadelphia Baltimore New York London Buenos Aires Hongkong Sydney Tokyo

    Google Scholar 

  • Huynh H, Yang X, Pollak M et al. (1996) Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. Biol Chem 271: 1016–1021

    Article  Google Scholar 

  • Jänicke F, Prechtl A, Thomssen C et al. for the German »Chemo-N0« Study Group (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93: 913–920

    Article  PubMed  Google Scholar 

  • Kahlert S, Nuedling S, van Eickels M et al. (2000) Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem 275: 18447–18453

    Article  PubMed  Google Scholar 

  • Knabbe C, Lippman ME, Wakefield LM et al. (1987) Evidence that transforming growth factor β is a hormonally regulated growth factor in human breast cancer cells. Cell 48: 417–428

    Article  PubMed  Google Scholar 

  • Kreienberg R, Volm T, Möbus V, Alt D (Hrsg) (2002) Management des Mammakarzinoms. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Kühn T, Bembenek A, Büchels H et al. (2003) Sentinel-Node-Biopsie beim Mammakarzinom — Interdisziplinär abgestimmter Konsensus der Deutschen Gesellschaft für Senologie für eine qualitätsgesicherte Anwendung in der klinischen Routine. Geburtsh Frauenheilk 63: 835–840

    Article  Google Scholar 

  • Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF 2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2 and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20: 2310–2318

    Article  PubMed  Google Scholar 

  • Levine MN, Bramwell VH, Pritchard KI et al. (1998) Randomized trial of intensive cyclophosphamide, epirubicin and fluouracil chemotherapy compared with cyclophosphamide, methotrexate and fluouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16: 2651–2658

    PubMed  Google Scholar 

  • Lück HJ, Thomssen C, Untch M et al. (2000) Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/Paclitaxel (ET) vs. Epirubicin/Cyclophosphamide (EC). A study of the AGO Breast Cancer Group. Proc ASCO: Abstract 280

    Google Scholar 

  • Bastert G, Schmidt-Matthiesen H, Wallwiener D (Hrsg) (2002) Mammakarzinome. In: Gynäkologische Onkologie. Schattauer, Stuttgart

    Google Scholar 

  • Mass N, Jonat W (2003) Aromatasehemmer in der adjuvanten Therapie des Mammakarzinoms. Gynäkologe 36: 103–109

    Google Scholar 

  • Mathieu M, Vignon F, Capony F et al. (1991) Estradiol down-regulates the mannose-6-posphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: a receptor saturation mechanism to increase the secretion of lysosomal proenzymes. Mol Endocrinol 5: 815–822

    PubMed  Google Scholar 

  • McGuire WL (1991) Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 83: 154–155

    PubMed  Google Scholar 

  • McGuire WL, Tandon AK, Alred DC, Chamness GC, Clark GM (1990) Commentaries. How to use prognostic factors in axillary node-negative breast-cancer patients. J Natl Cancer Inst 82: 1006–1015

    PubMed  Google Scholar 

  • Migliaccio A, Di Domenico M, Nola E et al. (1996) Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15: 1292–1300

    PubMed  Google Scholar 

  • Minckwitz G, Brunnert K, Costa SD et al. für die Organkommission »Mamma« der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) (2001) Evidenzbasierte Empfehlungen zur Primärbehandlung von Mammakarzinomen. Der Konsens der AGO-Organkommission 2001. www.kgu.de/zfg/ago-gravenbruch/ und www.ago-online.de

    Google Scholar 

  • Mukku VR, Stancel GM (1985) Regulation of epidermal growth factor receptor by estrogen. J Biol Chem 260: 9820–9824

    PubMed  Google Scholar 

  • Nabholtz JM, Falkson G, Campos D et al. (1999) A phase III trial comparing Doxorubicin (A) and Docetaxel (T) (AT) to Doxorubicin and Cyclophosphamide (AC) as first line chemotherapy for MBC. Proc ASCO: Abstract 485

    Google Scholar 

  • NIH (2001) National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1–3, 2000. J Natl Cancer Inst 93: 979–989

    Google Scholar 

  • Peto R (2000) EBCTCG: Worldwide overview results. 23rd Annual San Antonio Breast Cancer Symposium, December 6–9, 2000

    Google Scholar 

  • Peto J, Mack TM (2000) High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 26: 411–414

    Article  PubMed  Google Scholar 

  • Pietras RJ, Arboleda J, Reese DM et al (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435–2446

    PubMed  Google Scholar 

  • Prechtl A, Harbeck N, Thomssen C et al. (2000) Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer. Int J Biol Markers 15: 73–78

    PubMed  Google Scholar 

  • Pritchard K, O'Malley FA, Andrulis I, Shepherd LE, Tu D, Levine MN, Bramwell VH (2002) Prognostic and predictive value of HER2/neu in a randomized trial comparing CMF to CEF in premenopausal women with axillary lymph node positive breast cancer (NCIC CTG MA.5). ASCO: Abstract 165

    Google Scholar 

  • Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138–140

    PubMed  Google Scholar 

  • Revillion F, Bonneterre J, Peyrat JP et al. (1998) ERB-B2 oncogene in human breast cancer and its clinical significance. European J Cancer 34: 791–808

    Article  Google Scholar 

  • Roggel F, Hocke S, Lindemann K et al. (2003) Minimal residual disease in breast cancer and gynaecological malignancies: phenotype and clinical relevance. Rec Results Cancer Res 162: 89–100

    Google Scholar 

  • Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S (1989) Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 7: 1239–1251

    PubMed  Google Scholar 

  • Schaller G (2001) Metastasiertes Mammakarzinom: Welche Patientinnen profitieren von einer Antikörpertherapie? Dt Ärztebl 9: A3014–A3015

    Google Scholar 

  • Schulz KD, Albert US und die Mitglieder der Planungsgruppe und Leiter der Arbeitsgruppen Konzertierte Aktion Brustkrebs-Früherkennung in Deutschland (2003) Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland. Zuckschwerdt, München Wien New York

    Google Scholar 

  • Silvestrini R, Daidone MG, Luisi A, Mastore M, Leutner M, Salvadori B (1997) Cell proliferation in 3800 node-negative breast cancers: consistency over time of biological and clinical information provided by the 3H-thymidine labelling index. Int J Cancer 74: 122–127

    Article  PubMed  Google Scholar 

  • Treeck O, Diedrich K, Ortmann O (2003) Neue Perspektiven in der Therapie gynäkologischer Malignome. Gynäkologe 36: 117–124

    Google Scholar 

  • Treeck O, Diedrich K, Ortmann O (2003) The activation of an extracellular signal-regulated kinase by oestradiol interferes with the effects of trastuzumab on HER2 signalling in endometrial adenocarcinoma cell lines. Eur J Cancer 39: 1302–1309

    Article  PubMed  Google Scholar 

  • UICC (2002) TNM, Classification of Malignant Tumours, 6th edn

    Google Scholar 

  • Veronesi U (2002) Brusterhaltende Operation, Sentinellymphknotenbiopsie und intraoperative Radiotherapie am European Institute of Oncology. In: Untch M, Sittek H, Bauerfeind I, Konecny G, Reiser M, Hepp H (Hrsg) Diagnostik und Therapie des Mammakarzinoms — State of the art 2002. Zuckschwerdt, München Wien New York, S 174–180

    Google Scholar 

  • Veronesi U, Bonadonna G, Zurida S et al. (1995) Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 222: 612–618

    PubMed  Google Scholar 

Download references

Authors
  1. H.-C. Kolberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Friedrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Lemke
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Ratzeburger Allee 160, 25538, Lübeck

    Michael Friedrich , Ricardo Felberbaum , Sascha Tauchert  & Klaus Diedrich , ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Kolberg, HC., Friedrich, M., Lemke, A. (2005). Maligne Erkrankungen der Brustdrüse. In: Friedrich, M., Felberbaum, R., Tauchert, S., Diedrich, K. (eds) Manual Gynäkologische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26780-8_2

Download citation

  • DOI: https://doi.org/10.1007/3-540-26780-8_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-22900-1

  • Online ISBN: 978-3-540-26780-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation